A couple weeks after activist attack, GlaxoSmithKline unveils big plans to create a UK biotech hub

Nicole DeFeudis

Editor

A couple weeks after activist investor Elliott began its long-awaited attack on CEO Emma Walmsley, GlaxoSmithKline has unveiled a plan to sell over a third …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

A couple weeks after activist attack, GlaxoSmithKline unveils big plans to create a UK biotech hub

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

FDA says Ozempic, Wegovy shortage is over

How AI can address ongoing challenges in the life sciences industry

A cou­ple weeks af­ter ac­tivist at­tack, Glax­o­SmithK­line un­veils big plans to cre­ate a UK biotech hub

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

A couple weeks after activist attack, GlaxoSmithKline unveils big plans to create a UK biotech hub